Dysregulation of Axl and its ligand growth arrest-specific 6 is implicated in the pathogenesis of several human cancers. In this study, we have used RNAi and monoclonal antibodies to assess further the oncogenic potential of Axl. Here we show that Axl knockdown reduces growth of lung and breast cancer xenograft tumors. Inhibition of Axl expression attenuates breast cancer cell migration and inhibits metastasis to the lung in an orthotopic model, providing the first in vivo evidence that links Axl directly to cancer metastasis. Axl knockdown in endothelial cells impaired tube formation and this effect was additive with anti-vascular endothelial growth factor (VEGF). Further analysis demonstrated that Axl regulates endothelial cell functions by modulation of signaling through angiopoietin/Tie2 and Dickkopf (DKK3) pathways. We have developed and characterized Axl monoclonal antibodies that attenuate non-small cell lung carcinoma xenograft growth by downregulation of receptor expression, reducing tumor cell proliferation and inducing apoptosis. Our data demonstrate that Axl plays multiple roles in tumorigenesis and that therapeutic antibodies against Axl may block Axl functions not only in malignant tumor cells but also in the tumor stroma. The additive effect of Axl inhibition with anti-VEGF suggests that blocking Axl function could be an effective approach for enhancing antiangiogenic therapy.
Introduction
Axl belongs to the subfamily of receptor tyrosine kinases (RTKs) that also includes Tyro3 and Mer (TAM; Lai and Lemke, 1991; O'Bryan et al., 1991) . The TAM receptors are characterized by a combination of two immunoglobin-like domains and dual fibronectin type III repeats in the extracellular region and a cytoplasmic kinase domain. The ligands for TAM receptors are Gas6 (growth arrest-specific 6) and protein S, two vitamin K-dependent proteins that exhibit 43% amino-acid sequence identity and share similar domain structures (Stitt et al., 1995; Varnum et al., 1995) . Each protein has a N-terminal Gla domain containing 11 g-carboxyglutamic acid residues, followed by four epidermal growth factor-like modules, and a C-terminal sex hormone-binding globulin (SHBG)-like structure consisting of two tandem laminin G domains. The SHBG domain is both necessary and sufficient for TAM receptor binding and activation, whereas the Gla domain binds the negatively charged membrane phospholipids and plays an important role in TAM-mediated phagocytosis of apoptotic cells (Hasanbasic et al., 2005; Sasaki et al., 2006) . Axl can also exist as a soluble molecule, which is generated by ADAM10 (activity of disintergrin-like metalloproteinase 10)-mediated proteolysis and is associated with Gas6 in mouse serum (Budagian et al., 2005a) . The biological function of sAxl has not been characterized.
TAM activation and signaling has been implicated in multiple cellular responses including cell survival, proliferation, migration and adhesion (Hafizi and Dahlba¨ck, 2006) . TAM receptor signaling has been shown to regulate vascular smooth muscle homeostasis (Korshunov et al., 2006 (Korshunov et al., , 2007 , platelet function, thrombus stabilization (Angelillo-Scherrer et al., 2001; Gould et al., 2005) and erythropoiesis (AngelilloScherrer et al., 2008) . TAM receptors are also implicated in the control of oligodendrocyte cell survival (Shankar et al., 2006) and in the regulation of osteoclast function (Katagiri et al., 2001) . Recent studies in knockout mice have revealed that TAM receptors play pivotal roles in innate immunity (Lemke and Rothlin, 2008) . TAM inhibits inflammation in macrophages and dendritic cells (Sharif et al., 2006; Rothlin et al., 2007) , promotes the phagocytosis of apoptotic cells (Lu et al., 1999; Prasad et al., 2006) and stimulates the differentiation of natural killer cells (Caraux et al., 2006) . In many of these instances, the primary downstream TAM signaling pathway appears to be PI3K/AKT pathway (Angelillo-Scherrer et al., 2001; Keating et al., 2006; Shankar et al., 2006) ; however, the Janus kinase-STAT pathway is essential for TAM-mediated immune responses (Rothlin et al., 2007) . In addition, cooperative interaction between TAM receptor and cytokine receptor signaling network is required for many TAM-regulated biological functions (Budagian et al., 2005b; Rothlin et al., 2007) .
Axl was originally cloned from patients with chronic myelogenous leukemia and, when overexpressed, it exhibits transforming potential (Janssen et al., 1991; O'Bryan et al., 1991) . Axl overexpression has been reported in a variety of human cancers (Craven et al., 1995; Ito et al., 1999; Berclaz et al., 2001; Sun et al., 2004; Shieh et al., 2005) , and is associated with invasiveness and metastasis in lung (Shieh et al., 2005) , prostate (Sainaghi et al., 2005) , breast (Meric et al., 2002) , and gastric cancers (Wu et al., 2002) as well as in renal cell carcinoma (Chung et al., 2003) and glioblastoma (Hutterer et al., 2008) . A recent study showed that Axl overexpression via a 'tyrosine kinase switch' leads to resistance to imatinib in gastrointestinal stromal tumors (Mahadevan et al., 2007) . Axl expression is induced by chemotherapy drugs and overexpression of Axl confers drug resistance in acute myeloid leukemia (Hong et al., 2008) . Axl has also been shown to regulate endothelial cell migration and tube formation (Holland et al., 2005) . These findings suggest that Axl may be involved in the regulation of multiple aspects of tumorigenesis.
In this study, we have used RNAi and monoclonal antibodies to further examine the oncogenic potential of Axl. We show that Axl expression promotes non-small cell lung carcinoma (NSCLC) and breast cancer xenograft tumor growth. Inhibition of Axl expression attenuated MDA-MB-231 migration and inhibited lung metastasis of these cancer cells in an orthotopic model. Axl knockdown in endothelial cells impaired tube formation and this effect is additive with anti-vascular endothelial growth factor (VEGF). Further, we obtained evidence that Axl regulates endothelial cell functions by modulation of signaling through angiopoietin/Tie2 and Dickkopf-homologue 3 (DKK3) pathways. In addition, we have developed and characterized Axl monoclonal antibodies that block Gas6 binding, downregulate Axl expression and phosphorylation, inhibit Gas6-depedent cell proliferation and attenuate A549 xenograft tumor growth.
Results

Axl is frequently overexpressed in cancer cell lines
We used microarray analysis to screen a large panel of cancer cell lines representing various tumor types for Axl mRNA expression. Axl exhibited a wide range of expression, from barely detectable to extremely high levels, even within the same tissue type (Figure 1a) . Axl was overexpressed in a variety of cancer cell lines, with highest frequency in glioblastoma multiform (GBM) and pancreatic cancer. We used immunoblotting to determine Axl protein levels in selected cancer cell lines. Axl was highly expressed in all the cancer cell lines tested, including GBM, prostate, pancreatic, colon, NSCLC and breast cancers (SH-SY5Y, a neuroblastoma cell line which is known not to express Axl was used as a negative control; Figure 1b ). In addition, the ligand Gas6 was coexpressed in these cancer cell lines (Figure 1b) . To determine whether Axl is constitutively activated, we measured the level of phosphorylated Axl by enzyme-linked immunosorbent assay (ELISA). All cancer cell lines tested had detectable levels of phosphorylated Axl (Figure 1c) . Treatment of cells with exogenously added Gas6 could significantly induce further Axl phosphorylation in A172, Calu1 and H1299 cells, but not in other cell lines. These results suggest that Axl is constitutively activated to various levels in tumor cell lines, probably via autocrine action of endogenous Gas6.
Axl knockdown in cancer cell lines reduces cell viability and attenuates their migration To examine the functional significance of Axl expression in tumor growth, migration and metastasis, we established stable cell lines, in which the expression of Axl could be knocked down by doxycycline-inducible AxlshRNA. We initially tested six Axl siRNA sequences for their ability to inhibit Axl expression in human umbilical vein endothelial cells (HUVECs). All six Axlspecific siRNAs reduced Axl protein levels by more than 90% as measured by fluorescence-activated cell sorting (FACS) 48 h posttransfection (Supplementary Figures 1A  and B) , whereas the control siRNA had no effect on Axl protein. We then used short hairpin RNA (shRNA) based on one of the Axl siRNAs (Axl-4) to generated stable, inducible Axl knockdown cell lines. These cell lines were generated as pools to circumvent clonal variation.
Treatment of cancer cell lines stably expressing AxlshRNA with doxycycline (Dox) for 72 h resulted in almost complete inhibition of Axl protein expression (Figure 2a ). Axl knockdown was accompanied by inhibition of downstream signaling events. Although Gas6 induced Akt phosphorylation in parental H1299 and H1299AxlshRNA cells without Dox treatment, Gas6-induced Akt phosphorylation was completely abolished in cells with Axl knockdown, similar to cells treated with soluble receptor AxlFc (Figure 2b) .
To test the effect of Axl knockdown on cancer cells in vitro, we performed cell proliferation and migration assays. Induction of Axl knockdown by Dox reduced cell viability in A549 (50%) and MDA-MB-231 (33%; Figure 2c ). Although Axl knockdown in H1299 cells did not affect cell viability in the absence of Gas6, it abolished Gas6-mediated increase in viability of cells cultured in low serum (Figure 2c ). Axl knockdown significantly attenuated the motility MDA-MB-231 (40%) and A549 (48%) cells (Figure 2d ). These results suggest that Gas6-Axl signaling promotes cancer cell growth and migration to various degrees depends on the cellular context.
Axl knockdown reduces tumor growth in xenograft models
To evaluate whether Axl expression is required for cancer cell growth in vivo, we tested the effect of Axl Multiple functions of Axl in tumorigenesis Y Li et al knockdown on the growth of NSCLC A549 and H1299, and breast cancer MDA-MB-231 xenografts in mice. Cells stably expressing AxlshRNA were implanted subcutaneously in nude (A549 and H1299) or SCID (MDA-MB-231) mice, respectively. For the A549 and H1299 models, mice were randomized into treatment and control groups after implantation and administered with Dox or sucrose, respectively, in drinking water. As compared with untreated mice, Dox-induced Axl silencing resulted in a markedly impaired ability of A549 tumors to grow (Figure 3a) . Dox-induced Axl knockdown in H1299 cells resulted in a moderate (25%) inhibition of tumor growth in nude mice (Figure 3b (17) melanoma (11) ovarian (24) pancreatic (9) prostate (51) 
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in cancer metastasis remains to be determined. We approached this question by utilizing an orthotopic model and monitoring tumor metastasis by bioluminescence imaging. We generated a stable MDA-MB-231 cell line that expresses both a Dox-inducible AxlshRNA and a luciferase reporter gene. This cell line displayed high levels of bioluminescence as determined by an in vitro luciferase assay (data not shown). Figure 4a outlines the experimental design for our study. At first we asked whether Axl expression affects dissemination of breast cancer cells to the distant organ sites. Doxycycline treatment was started the day after cell implantation. Primary tumors were well established 2 weeks after implantation. The primary tumors were removed when they reached the size of 1000 mm 3 , and metastasis to the lung was monitored for 5 weeks after removal of the primary tumors. Five weeks after removal of the primary tumors, large metastatic foci were detected in the lungs of three out of five mice in the control group, whereas there was no sign of lung metastasis in the Dox-treated animals (n ¼ 5; Figure 4b , group 1). The presence of tumor foci in the lungs was confirmed by hematoxylin and eosin (H&E) staining (Figure 4c ), and by c-Met (a protein known to be expressed in MDA-MB-231 cells) immunohistochemistry to definitively mark human tumor cells (not shown). These results suggest that Axl promotes breast cancer cell metastasize to the lung.
We then asked whether Axl expression is required for metastatic growth once cancer cells have colonized the lung. To address this question, we allowed primary tumor size to reach 1000 mm 3 , removed the primary Axl knockdown in HUVECs impairs endothelial tubule formation Previous study has shown that Axl is overexpressed not only in tumors but also in the surrounding vascular cells (Hutterer et al., 2008) . To evaluate further the potential role of Axl in the regulation of angiogenesis, we tested the effect of Axl knockdown on endothelial tube formation. FACS analysis demonstrated expression of Axl on the surface of HUVECs (Figure 5a ). Forty-eight hours posttransfection, Axl protein level was downregulated more than 90% in HUVECs transfected with Axl-specific siRNA, whereas the control luciferase siRNA (GL2) had no effect (Figure 5a ). Axl knockdown in HUVECs did not significantly affect cell growth (Supplementary Figure 1C) .
We next used a primary HUVEC/PASMC (pulmonary artery smooth muscle cell) coculture branching tube formation assay to assess the importance of Axl in angiogenesis. Tube formation as quantified by tube length was reduced B40% in HUVECs transfected with Axl siRNA compared with cells transfected with the control siRNA (Figure 5b ). These results suggest that Axl is involved in the regulation of endothelial tube morphogenesis.
Axl modulates expression of angiogenic factors Dickkopf-homologue 3 and angiopoietin-2 To gain insight into the mechanisms involved in the regulation of angiogenesis by Axl, we performed gene profiling in HUVECs transfected with Axl or control siRNAs. Figure 6a lists the top eight genes that were upor downregulated in HUVECs after Axl knockdown. Two of the genes, angiopoietin-2 (Ang-2) and DKK3, are known regulators of angiogenesis. We confirmed the (Figure 6b ). In addition, the amount of the DKK3 and Ang-2 proteins in HUVEC lysates and in the culture medium also changed following Axl knockdown as measured by ELISA (Supplementary Figure 2) . To understand the relationship between Axl and DKK3 or Ang-2, we tested the effect of DKK3 and Ang-2 siRNA knockdown on Axl expression. Knockdown of neither DKK3 nor Ang-2 affected Axl protein level (Supplementary Figure 2 ). In addition, knockdown of DKK3 had no effect on Ang-2, nor did Ang-2 knockdown affect DKK3 expression (Supplementary Figure 2) . We next tested the effect of DKK3 and Ang-2 siRNAs on endothelial tube formation. Knockdown of DKK3 by RNAi reduced tube formation to a similar extent as did Axl knockdown, whereas Ang-2 siRNA alone had no significant effect on tubule formation (Figure 6c ). These results suggest that both DKK3 and Ang-2 are downstream targets of Axl and that their expression may be regulated by different signaling pathways.
Axl knockdown has additive effect with anti-VEGF As VEGF is a major factor that regulates endothelial cell functions, we tested the effect of Axl knockdown together with anti-VEGF monoclonal antibody in tube formation assay. Treatment of cells with anti-VEGF alone resulted in dose-dependent reduction in tube formation (not shown), Axl knockdown together with anti-VEGF resulted in enhanced inhibition of tube formation (Figure 7) , similar results were seen with DKK3 knockdown (Figure 7) . These results suggest that downregulation of Axl expression has an additive effect with anti-VEGF to inhibit endothelial tube formation.
Generation of monoclonal antibodies that block Axl function
Our validation data using RNAi suggested that Axl is involved in tumor growth, metastasis as well as in the regulation of angiogenesis. We therefore set out to develop monoclonal antibodies against Axl. 
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We developed a cell-based assay to directly test the ability of Axl mAbs to block Axl/Gas6-mediated cell growth. We generated a stable cell line in Baf3 pro-B cells that overexpresses Axl (Supplementary Figure 3A) . Figure 3B) , which could be inhibited by AxlFc in a dose-dependent manner (Supplementary Figure 3C) . We immunized mice with human Axl extracellular domain (ECD), and screened a panel of hybrid supernatants using this assay. We identified four antibodies that blocked Gas6-induced Baf3Axl cell growth (Supplementary Figure 3D) . Purified antibodies showed dose-dependent inhibition of Baf3Axl cell growth, with the strongest blocker, 12A11, exhibiting an IC50 of B100 ng/ml ( Figure 8A) .
Expression of Axl in Baf3 cells resulted in Gas6-dependent growth (Supplementary
To understand the mechanisms of Axl inhibition by these mAbs, we further characterized these antibodies. Axl mAbs 3G9 and 8B5 blocked ligand binding to the receptor in solid-phase ELISA, whereas 12A11 and 4F8 had no effect on ligand binding (Figure 8Ba ). We confirmed this result by using FACS to determine the ability of Axl mAbs to block Gas6 binding to cell surface Axl on A549 cells (Figure 8Bb ). Axl mAbs 12A11, 8B5 and 3G9 downregulated receptor expression in A549 cells, whereas 4F8 had no effect ( Figure 8C ). 4F8 was the only antibody that detected Axl in western blotting, suggesting that it recognizes a linear epitope (data not shown). In addition, 12A11 and 3G9 inhibited Gas6-induced Axl phosphorylation in H1299 cells ( Figure 8C ).
These monoclonal antibodies did not cross-react with murine Axl (Supplementary Figure 4A) , nor did they cross-react with related receptors Tyro3 and Mer (Supplementary Figure 4B) . The Axl mAbs did not compete with each other in cross-blocking assays (data not shown), suggesting that they bind different epitopes. To localize the binding epitopes of mAbs, different portions of Axl ECD were in vitro transcribed and translated ( Figure 8D ) and then used as antigens in ELISA. The epitopes for 3G9 and 8B5 appeared to be 
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Axl mAbs inhibit A549 NSCLC xenograft tumor growth
To evaluate whether mAb inhibition of Axl affects tumor cell growth in vivo, A549 cells were implanted subcutaneously in nude mice. When the tumor size reached 100 mm 3 (Day 0 in Figure 9a ), animals were randomized and treated with either Axl mAbs or a control antibody at 30 mg/kg, twice weekly. Axl mAbs significantly attenuated A549 tumor growth compared with control, around 40% inhibition 40 days postdosing (Figure 9a) . To investigate the mechanism of tumor growth inhibition by Axl mAbs, we performed a pharmacodynamic study. Tumors were excised at 0, 24, 48 and 72 h after administration of antibodies and tumor lysate was generated. Western blotting analysis showed that the Axl mAbs downregulated Axl expression in tumors at 24 h postdosing, which was sustained through 72 h (Figure 9b ). Ki67 and caspase 3 staining of tumor samples showed that treatment of tumors with Axl mAb 12A11 resulted in 20% decrease in Ki67 staining ( Figure 9c ) and approximately 50% increase in caspase 3 staining (not shown) 72 h postdosing. These results suggest that Axl mAbs attenuate A549 xenograft growth by downregulation of receptor expression, which in turn leads to increased apoptosis and deceased cell proliferation of tumor cells. These results are consistent with Axl knockdown in A549 cells, confirming that Axl plays an important role in the regulation of tumor growth of this NSCLC cell line.
Discussion
In this study, we have investigated various roles of Axl in tumorigenesis including tumor growth, metastasis as well as angiogenesis. We used inducible shRNA to inhibit Axl expression in human cancer cell lines and demonstrated that Axl expression promotes tumor growth in NSCLC and breast cancer models. Previous studies showed that Axl expression promotes tumor Multiple functions of Axl in tumorigenesis Y Li et al growth in xenograft models of glioblastoma (Vajkoczy et al., 2006) and breast cancer (Holland et al., 2005) , using an Axl dominant-negative mutant or shRNA, respectively. However, in both of these studies, tumor growth rate was compared between a control cell line and a cell line, in which either Axl or its signaling was downregulated before implantation into mice. Although this approach is useful, it does not assess the direct impact of Axl inhibition on tumor growth. Our approach took the advantage of inducible expression of AxlshRNA and measured the growth of the same cell line in the presence or absence of Axl expression. Our results show that the impact of Axl expression on tumor growth depends on the cell model used. Although Axl knockdown in A549 NSCLC almost completely inhibited tumor growth, the effect of Axl knockdown on H1299 NSCLC and MDA-MB-231 breast cancer was moderate (about B30% growth inhibition). The higher sensitivity of A549 cells to Axl knockdown may be due to the presence of an increased gene copy number of Axl in these cells (unpublished result).
Metastasis accounts for approximately 90% of all cancer deaths; and of all processes involved in carcinogenesis, local invasion and formation of metastasis are clinically the most relevant. Recent experimental progress has identified several molecular pathways and cellular mechanisms that underlie the multistage process of metastasis. These include tumor invasion, tumor cell dissemination through the bloodstream or lymphatic system, colonization of distant organs and outgrowth of metastases (Christofori, 2006) . Axl expression is associated with invasiveness and metastasis in various cancers including breast (Meric et al., 2002; Zhang et al., 2008) , lung (Shieh et al., 2005) and gastric (Sainaghi et al., 2005) cancers, as well as in glioblastoma (Hutterer et al., 2008) . The involvement of Axl in promoting cancer cell migration and invasion has been demonstrated in vitro (Vajkoczy et al., 2006; Tai et al., 2008; Zhang et al., 2008) . In breast cancer models, ectopic expression of Axl was sufficient to confer a highly invasive phenotype to weakly invasive MCF7 cells. Conversely, inhibition of Axl signaling by shRNA knockdown or an anti-Axl antibody decreased mobility and invasiveness of highly invasive breast cancer cells (Zhang et al., 2008) . Although these studies established a role for Axl in promoting cell migration and invasion knockdown by shRNA completely abolished the ability of cells emerging from the primary tumors to colonize the lungs. However, once metastatic foci had established in the lung, Axl did not seem to have a significant impact on the out growth of the metastases. These results implicate Axl in early stages of MDA-MB-231 cancer cell metastasis, and provided the first in vivo evidence that directly links Axl to metastasis.
Gas6/Axl signaling plays an important role in vascular biology by modulating survival and migration of vascular smooth muscle cells and endothelial cells (Melaragno et al., 1999) . The expression of Gas6/Axl is upregulated in injured arteries and Gas6 induces class A scavenger receptor through activation of PI3K/Akt, leading to the formation of foam cells, an important step in atherosclerosis (Cao et al., 2001) . Activation of Axl signaling mediates antiapoptotic effects of laminar shear stress in endothelial cells possibly through its association with avb3 integrin complex (D'Arcangelo et al., 2006) . Axl and Gas6 are coexpressed in tumor associated vascular cells in gliomas (Hutterer et al., 2008) . In primary human breast cancer samples, we found strong Axl staining in tumor stromal cells (unpublished observation). Therefore Axl may impact tumorigenesis not only in tumor cells but also by modulating tumor stromal function such as angiogenesis. In this study, we have performed experiments to understand the mechanisms involved in the regulation of endothelial cell functions by Axl. Our data show that Axl expression is not required for endothelial cell proliferation, as Axl knockdown by RNAi had little impact on the growth of these cells. However, inhibition of Axl expression impaired endothelial tube formation.
To understand the mechanisms involved, we performed mRNA expression profiling to identify genes that may be modulated by Axl expression. Axl knockdown 
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Y Li et al resulted in the downregulation of DKK3 and upregulation of Ang-2, two factors known to be involved in angiogenesis. DKK3 is among the Dickkopf family of secreted modulators of Wnt signaling (Krupnik et al., 1999) , and is strongly expressed in the developing heart and blood vessels of mice and chickens (Monaghan et al., 1999) . A recent study demonstrated DKK3 protein expression in blood vessels of highly vascularized neoplasms, including GBM, high-grade non-Hodgkin's lymphoma, melanoma and colorectal carcinomas (Monaghan et al., 1999) . Stable overexpression of murine DKK3 in B16F10 cells significantly increased microvessel density in the C57/BL6 melanoma model. In addition, an in vitro study in primary endothelial colonyforming cells showed that siRNA knockdown of DKK3 did not significantly affect cell proliferation, but decreased tube formation in matrigel (Untergasser et al., 2008) . These results are similar to our findings in HUVEC after Axl or DKK3 knockdown. Axl knockdown in HUVECs led to upregulation of Ang-2. The angiopoietin signaling system plays a key role in the regulation of angiogenesis, vascular homeostasis and vascular regression (Yancopoulos et al., 2000) . This signaling system consists of angiopoietin 1 and 2 and their receptor Tie2 (Dumont et al., 1994) . Ang-1 is an agonist that supports EC survival and endothelium integrity (Suri et al., 1998) through the PI3K/Akt signaling pathway (Peters et al., 2004) . On the other hand, Ang-2 (Maisonpierre et al., 1997) is a signaling antagonist and inhibits the action of Ang-1 to promote vessel destabilization. In the presence of VEGF, Ang-2 provides an important angiogenic stimulus (Yancopoulos et al., 2000) . However, when VEGF signaling is inhibited or absent, the destabilizing action of Ang-2 on vessels leads to cell death and capillary regression (Yancopoulos et al., 2000) . Our results demonstrate that Axl knockdown is additive with anti-VGEF to inhibit endothelial tube formation. This additive effect may be mediated through upregulation of Ang-2 when Axl expression is inhibited.
Taken together, our results suggest the following model for modulation of endothelial cell function by Axl. Expression of Axl in EC results in upregulation of the proangiogenic factor DKK3 and downregulation of Ang-2, which in turn facilitates signaling of Ang-1/Tie2 and results in the increase in angiogenesis.
The multiple roles that Axl plays in tumorigenesis make it an attractive therapeutic target for cancer. Anti-Axl antibodies are specific reagents that can be used to investigate the role of Axl in tumorigenesis, and provide therapeutic potential to inhibit Axl-dependent signaling in patients. An antagonistic mAb can achieve its function by various mechanisms: (1) blocks ligand binding to the receptor, (2) promotes receptor degradation, (3) blocks receptor dimerization or (4) mediates antibody-dependent cell-mediated cytotoxicity. As many tumors may exhibit ligand-independent activation of Axl, it is important to develop and compare mAbs that act through different modes of action, and select the lead mAb based on efficacy.
In this study, we have characterized a panel of hybridoma antibodies against Axl. We developed a cell-based screen for monoclonal antibodies that block Axl biological function. The mAbs we characterized here include two (3G9 and 8B5) that block ligand binding to the receptor, and one (12A11) that does not interfere with ligand binding, but inhibits receptor phosphorylation. All three mAbs induce downregulation of receptor expression. Most importantly, these mAbs attenuated A549 NSCLC tumor growth. These results not only confirm the role of Axl in promoting tumor growth as indicated by the shRNA studies, but also suggest that monoclonal antibodies may provide an effective strategy for treatment of cancers that overexpress Axl. As these mAbs do not cross-react with murine Axl, it was not possible to assess the importance of Axl for tumor angiogenesis in vivo and its impact on the tumor stroma. We are currently developing crossreacting mAbs to investigate these potential functions of Axl in vivo.
In summary, we have validated a role for Axl in promoting tumor growth and provided the first evidence that Axl expression is required for metastasis of breast cancer cells to the lung. We demonstrated that Axl enhances endothelial tube formation by acting through the angiopoietin and DKK3 signaling system. Our data suggest that therapeutic antibodies against Axl could block Axl functions not only in the tumor itself but also possibly in the surrounding stroma. The additive effect of Axl inhibition with anti-VEGF suggests that blocking Axl function might be a useful approach for enhancing antiangiogenic therapy and warrant further investigation.
Materials and methods
Antibodies and cell lines information as well as protocols including siRNA transfection, generating inducible AxlshR-NA cell lines, proliferation and migration assays, coculture, microarray, generation and characterization of Axl mAbs are provided in Supplementary materials.
Xenograft experiments
All studies were conducted in accordance with the Guidance for the Care and Use of Laboratory Animals (NIH), and approved by Institutional Animal Care and Used Committee (IACUC). The detailed protocols are described in Supplementary materials.
